Product News
Filter News
Found 273,315 articles
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
Nexus Pharmaceuticals Launches Baclofen Injection, USP
3/18/2024
Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP.
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
3/18/2024
Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.
-
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
3/18/2024
Arch Biopartners Inc. announced today that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus.
-
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
3/18/2024
ZyVersa Therapeutics, Inc. announces Institutional Review Board (IRB) approval of the Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease.
-
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
3/18/2024
Aligos Therapeutics, Inc. today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.
-
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
3/18/2024
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced that more than three million ICLs have been sold globally.
-
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
3/18/2024
Fennec Pharmaceuticals Inc. and Norgine announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand.
-
Avenacy Announces New Product Launches and Participation in DCAT Week 2024
3/18/2024
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Fosaprepitant for Injection and Fulvestrant Injection in the United States.
-
Genseq Selects Sapio LIMS to Power Best-in-Class Next-Generation Sequencing Services
3/18/2024
Genseq, a Dublin-based, CAP-accredited laboratory providing a range of services for biopharma and clinical research, has adopted the science-aware™ lab informatics platform from Sapio Sciences to manage its next-generation sequencing and biobanking workflows.
-
Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System
3/18/2024
Aquedeon Medical, Inc. is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical trial to study for the Duett(TM) Vascular Graft System.
-
AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801
3/18/2024
AliveGen USA Inc. is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801.
-
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
3/18/2024
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI ® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease.
-
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
3/18/2024
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
-
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
3/18/2024
Inspira™ Technologies OXY B.H.N. Ltd., a breakthrough medical technology company, is excited to announce the AMAR submission for approval of the INSPIRA™ ART100, marking a significant milestone in Inspira's venture into new markets.
-
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
3/18/2024
Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.
-
Phase III clinical trial of pediatric subjects with PMM2-CDG begins crossover to open label epalrestat
3/18/2024
Maggie's Pearl, a collaboration between Perlara, Maggie's Cure, and the Mayo Clinic, announced that the Phase III trial of oral epalrestat therapy in pediatric subjects with PMM2-CDG (formerly, Congenital Disorder of Glycosylation Type 1a) has been green-lighted to transition to open label.
-
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
3/18/2024
Natera, Inc. announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease -guided adjuvant treatment in stage II colorectal cancer patients.
-
Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference
3/18/2024
Brenig Therapeutics presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17, 2024.
-
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
3/18/2024
Oragenics, Inc. announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial.